MW EG169 articl NS 20160223171404 captis executive search management consulting leadership board services

Acadia Pharmaceuticals stock price target cut to $26 from $40 at Canaccord Genuity

MW EG169 articl NS 20160223171404 captis executive search management consulting leadership board services

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm’s products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

This is not a CAPTIS article. Originally, it was published here.